Страна: Австралия
Език: английски
Източник: Department of Health (Therapeutic Goods Administration)
digoxin, Quantity: 250 microgram
Aspen Pharma Pty Ltd
Tablet, uncoated
Excipient Ingredients: lactose monohydrate; maize starch; rice starch; oxidised maize starch; magnesium stearate
Oral
30 tablets, 500 (E), 100 (E), 250 tablets, 1000 tablets
Medicine Registered
(S4) Prescription Only Medicine, Not scheduled. Not considered by committee
Congestive heart failure; Lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. It is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. Lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. Atrial fibrillation: Because Lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. It will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. Paroxysmal atrial tachycardia: Lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.
Visual Identification: White biconvex scored tablet marked X3A.; Container Type: Bottle; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Registered
1991-08-02